Table 1.
Initial principles identified by discussion | Core principles following the completion of the consensus process |
---|---|
(i) Commitment to research | (i) Commitment to research |
(ii) Regulatory body education | (ii) Patient engagement and better communication with stakeholders |
(iii) New endpoints in clinical trials | (iii) Regulatory body education and reimbursement |
(iv) Healthcare and social care: personalised care | (iv) More therapy options with better benefit: risk ratios |
(v) More therapy options | (v) Early diagnosis and management of MS |
(vi) MS centres of excellence | (vi) Multidisciplinary MS centres |
(vii) Informed, shared decision-making | |
(viii) Better communication between stakeholders | |
(ix) Cost and reimbursement | |
(x) Drugs with better risk: benefit profiles | |
(xi) Early treatment | |
(xii) Patient engagement and enablement |
The consensus process included questions and discussions leading to some merging or modification of original principles that expressed similar or overlapping aspirations for MS care; accordingly items in the right column are not identical to those in the left column from which they were derived. See text for further details.